Pooled evidence from CVOTs of T2D demonstrates substantial racial/ethnic differences in the cardiorenal effects of SGLT2-Is and GLP1-RAs in patients with T2D, with most benefits observed among White and Asian populations. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.